Search Results - "Liefaard, Lia"

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study by Voit, Thomas, Prof, Topaloglu, Haluk, Prof, Straub, Volker, Prof, Muntoni, Francesco, Prof, Deconinck, Nicolas, MD, Campion, Giles, MD, De Kimpe, Sjef J, PhD, Eagle, Michelle, PhD, Guglieri, Michela, MD, Hood, Steve, PhD, Liefaard, Lia, PhD, Lourbakos, Afrodite, PhD, Morgan, Allison, BSc, Nakielny, Joanna, MB, Quarcoo, Naashika, PhD, Ricotti, Valeria, MB, Rolfe, Katie, MSc, Servais, Laurent, MD, Wardell, Claire, DPhil, Wilson, Rosamund, PhD, Wright, Padraig, MD, Kraus, John E, MD

“…Summary Background Duchenne muscular dystrophy is caused by dystrophin deficiency and muscle deterioration and preferentially affects boys…”
Get full text

Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain by Huntjens, Dymphy R., Liefaard, Lia C., Nandy, Partha, Drenth, Henk-Jan, Vermeulen, An

“…Background and Objective Tapentadol is a centrally acting analgesic with two mechanisms of action, µ-opioid receptor agonism and noradrenaline reuptake…”
Get full text

Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomography by Liefaard, Lia C., Ploeger, Bart A., Molthoff, Carla F. M., De Jong, Hugo W. A. M., Dijkstra, Jouke, Van Der Weerd, Louise, Lammertsma, Adriaan A., Danhof, Meindert, Voskuyl, Rob A.

“…Summary Purpose:  The purpose of the present investigation was to quantify alterations in GABAA receptor density in vivo in rats subjected to amygdala…”
Get full text

The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice by Verhaart, Ingrid E C, van Vliet-van den Dool, Laura, Sipkens, Jessica A, de Kimpe, Sjef J, Kolfschoten, Ingrid G M, van Deutekom, Judith C T, Liefaard, Lia, Ridings, Jim E, Hood, Steve R, Aartsma-Rus, Annemieke

“…Antisense-mediated exon skipping is currently in clinical development for Duchenne muscular dystrophy (DMD) to amend the consequences of the underlying genetic…”
Get full text

Decreased Efficacy of GABAA‐receptor Modulation by Midazolam in the Kainate Model of Temporal Lobe Epilepsy by Liefaard, Lia C., Gunput, Rou‐Afza F., Danhof, Meindert, Voskuyl, Rob A.

“…Purpose: The objective of this investigation was to characterize quantitatively the time‐dependent changes in midazolam (MDL) efficacy in the silent period…”
Get full text

Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis by Dimelow, Richard, Liefaard, Lia, Green, Yulia, Tomlinson, Ryan

“…Background and Objective Lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus, has greater severity in children versus adults…”
Get full text

Population Pharmacokinetic Analysis for Simultaneous Determination of B max and K D In Vivo by Positron Emission Tomography by Liefaard, Lia C., Ploeger, Bart A., Molthoff, Carla F. M., Boellaard, Ronald, Lammertsma, Adriaan A., Danhof, Meindert, Voskuyl, Rob A.

“…Changes in GABA^sub A^-receptor density and affinity play an important role in many forms of epilepsy. A novel approach, using positron emission tomography…”
Get full text

Quantifying the Effectiveness of Dose Individualization by Simulation for a Drug With Moderate Pharmacokinetic Variability by Liefaard, Lia, Chen, Chao

“…Dose individualization can reduce variability in exposure. The objective of this work was to quantify, through pharmacokinetic (PK) simulation, the potential…”
Get full text

Alterations in GABAA receptor kinetics in epileptic rats studied in vivo using positron emission tomography by Liefaard, Lia C., Ploeger, B.A., Molthoff, C.F.M., Boellaard, R., de Jong, H.W.A.M., Lammertsma, A.A., Danhof, M., Voskuyl, R.A.

“…In order to study alterations in receptor kinetics in epilepsy, the full saturation method was applied to estimate Bmax and KD both in rats with increased…”
Get full text

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis by Richards, Duncan B, Cookson, Louise M, Barton, Sharon V, Liefaard, Lia, Lane, Thirusha, Hutt, David F, Ritter, James M, Fontana, Marianna, Moon, James C, Gillmore, Julian D, Wechalekar, Ashutosh, Hawkins, Philip N, Pepys, Mark B

“…Systemic amyloidosis is a fatal disorder caused by pathological extracellular deposits of amyloid fibrils that are always coated with the normal plasma…”
Get more information

Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro‐drug of miridesap by Richards, Duncan, Bamford, Mark, Liefaard, Lia, Haque, Nazneen, Lewis, Gareth, Storey, Jim, Fernando, Disala, Kumar, Subramanya, Thompson, Douglas, Holmes, Duncan S.

“…Background and Purpose Miridesap, a depleter of serum amyloid P component (SAP), forms an essential component of a novel approach to remove systemic amyloid…”
Get full text

A randomised, double‐blind, placebo‐controlled study of the LAG‐3‐depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis by D'Haens, Geert, Peyrin‐Biroulet, Laurent, Marks, Daniel J. B., Lisi, Edoardo, Liefaard, Lia, Beaton, Andrew, Srinivasan, Naren, Bouma, Gerben, Prasad, Naveen, Cameron, Raymond, Kayali, Zeid, Tarzi, Ruth, Hanauer, Stephen, Sandborn, William J.

“…Summary Background Selective depletion of T cells expressing LAG‐3, an immune checkpoint receptor that is upregulated on activated T cells, has been…”
Get full text

Depletion of LAG‐3+ T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781 by Ellis, Joanne, J.B. Marks, Daniel, Srinivasan, Naren, Barrett, Christine, Hopkins, Thomas G., Richards, Anna, Fuhr, Rainard, Albayaty, Muna, Coenen, Martin, Liefaard, Lia, Leavens, Karen, Nevin, Katherine L., Tang, Shuo, Hughes, Stephen A., Fortunato, Léa, Edwards, Ken, Cui, Yi, Anselm, Rabia, Delves, Christopher J., Charles, Emilie, Feeney, Maria, Webb, Thomas M., Brett, Sara J., Schmidt, Tim S., Stone, John, Savage, Caroline O.S., Wisniacki, Nicolas, Tarzi, Ruth M.

“…Activated T cells drive a range of immune‐mediated inflammatory diseases. LAG‐3 is transiently expressed on recently activated CD4+ and CD8+ T cells. We…”
Get full text

Time-to-Event Modeling of Left- or Right-Censored Toxicity Data in Nonclinical Drug Toxicology by Berges, Alienor, Cerou, Marc, Sahota, Tarjinder, Liefaard, Lia, Ambery, Claire, Zamuner, Stefano, Chen, Chao, Hénin, Emilie

“…A time-to-event (TTE) model has been developed to characterize a histopathology toxicity that can only be detected at the time of animal sacrifice. The model…”
Get full text

Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial by Flanigan, Kevin M, Voit, Thomas, Rosales, Xiomara Q, Servais, Laurent, Kraus, John E, Wardell, Claire, Morgan, Allison, Dorricott, Susie, Nakielny, Joanna, Quarcoo, Naashika, Liefaard, Lia, Drury, Tom, Campion, Giles, Wright, Padraig

“…Abstract Duchenne muscular dystrophy (DMD) is a progressive, lethal neuromuscular disorder caused by the absence of dystrophin protein due to mutations of the…”
Get full text

Effects of a novel sodium channel blocker, GSK2339345, in patients with refractory chronic cough by Smith, Jaclyn A, McGarvey, Lorcan P A, Badri, Huda, Satia, Imran, Warren, Francis, Siederer, Sarah, Liefaard, Lia, Murdoch, Robert D, Povey, Kathryn, Marks-Konczalik, Joanna

“…Voltage-gated sodium channels (VGSC) are important in the initiation and propagation of action potentials in afferent sensory nerve fibers responsible for…”
Get full text

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese Subjects by Ino, Hiroko, Doi, Yohei, Liefaard, Lia, Cookson, Louise, Chen, Chao, Itoh, Hiroshi, Igarashi, Harue, Nakano, Atsushi

“…This phase 1 study characterized the safety, tolerability, pharmacokinetics, and pharmacodynamics of miridesap (GSK2315698) following an intravenous (IV)…”
Get full text

Randomized Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2831781 in Healthy Japanese and White Participants by Liefaard, Lia, Hajduk, Eva, den Berg, Frans, Panoilia, Eirini, Bouma, Gerben, Lisi, Edoardo, Srinivasan, Naren, Cui, Yi, Gross, Annette S., Tarzi, Ruth, Marks, Daniel J.B.

“…This study investigated ethnic differences in the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2831781, an anti–lymphocyte activation…”
Get full text

Changes in GABA A receptor properties in amygdala kindled animals: In vivo studies using [ 11 C]flumazenil and positron emission tomography by Liefaard, Lia C., Ploeger, Bart A., Molthoff, Carla F. M., De Jong, Hugo W. A. M., Dijkstra, Jouke, Van Der Weerd, Louise, Lammertsma, Adriaan A., Danhof, Meindert, Voskuyl, Rob A.

“…Summary Purpose:   The purpose of the present investigation was to quantify alterations in GABA A receptor density in vivo in rats subjected to amygdala…”
Get full text

Decreased Efficacy of GABA A ‐receptor Modulation by Midazolam in the Kainate Model of Temporal Lobe Epilepsy by Liefaard, Lia C., Gunput, Rou‐Afza F., Danhof, Meindert, Voskuyl, Rob A.

“…Purpose: The objective of this investigation was to characterize quantitatively the time‐dependent changes in midazolam (MDL) efficacy in the silent period…”
Get full text